Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $63

Futu NewsDec 16 21:31 · Ratings

Oppenheimer Maintains Outperform on Keros Therapeutics, Lowers Price Target to $63

BenzingaDec 16 21:02 · Ratings

Keros Therapeutics Analyst Ratings

BenzingaDec 16 21:01 · Ratings

Analysts' Top Healthcare Picks: Aldeyra Therapeutics (ALDX), Keros Therapeutics (KROS)

TipRanksDec 16 20:50 · Ratings

Piper Sandler Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $40

Futu NewsDec 16 20:31 · Ratings

Keros Therapeutics Cut to Neutral From Buy by Guggenheim

Dow JonesDec 16 18:28 · Ratings